Bronchopulmonary dysplasia is associated with polyhydramnios in a scan for novel perinatal risk factors

Abstract

Background: The pathogenesis of bronchopulmonary dysplasia (BPD) is multifactorial, and there are limited data about prenatal exposures and risk of BPD. Study Design: Our study performed parallel analyses using a logistic regression model in a cohort of 4527 infants with data from a curated registry and using a phenome wide association study (PheWAS) based on ICD9/10-based phecodes. We examined 20 prenatal exposures from a neonatal intensive care unit (NICU) curated registry database related to pregnancy and maternal health as well as 94 maternal diagnosis phecodes with a PheWAS analysis. Result: In both the curated registry and PheWAS analyses, polyhydramnios was associated with an increased risk of BPD (OR 5.70, 95% CI 2.78–11.44, p = 1.37 × 10 −6 ). Conclusion: Our data suggest that polyhydramnios may be a clinical indicator of premature infants at increased risk for bronchopulmonary dysplasia. Combining curated registry data with PheWAS analysis creates a valuable tool to generate hypotheses.

Next-Generation Phenotyping: Introducing PhecodeX for Enhanced Discovery Research in Medical Phenomics

“…The increased specificity of phecodeX provides more granular coverage of the medical phenome intended to support new uses for phecodes and encourages further creative applications. Indeed, an alpha version of phecodeX has already been used in numerous publications, including studies on pregnancy and neonatal outcomes and hereditary cancer syndromes -studies that would not have been feasible without the additional granularity offered in phecodeX (Campbell, et al, 2023;Stead, et al, 2023;Zeng, et al, 2022). We acknowledge that v1.2 remains suitable for large-scale PheWAS, particularly for studies focused on common/complex diseases.…”

Next-generation phenotyping: introducing phecodeX for enhanced discovery research in medical phenomics

“…The increased specificity of phecodeX provides more granular coverage of the medical phenome intended to support new uses for phecodes and encourages further creative applications. Indeed, an alpha version of phecodeX has already been used in numerous publications, including studies on pregnancy and neonatal outcomes and hereditary cancer syndromes—studies that would not have been feasible without the additional granularity offered in phecodeX ( Zeng et al 2022 , Campbell et al 2023 , Stead et al 2023 ). We acknowledge that v1.2 remains a viable mapping for PheWAS.…”